Suraksha Diagnostic Ltd Opens On November 29. Check IPO Details Issue Date Price

EspressoLogy

Suraksha Diagnostic Ltd Opens On November 29. Check IPO Details Issue Date Price

November 28, 2024
Suraksha Diagnostic Ltd Opens On November 29. Check IPO Details Issue Date Price

Suraksha Diagnostic Limited is coming out with a fresh public issue to raise Rs. 846.25 crores from the market.

Below are the details of the Suraksha Diagnostic Limited IPO:

  • Issue opens – November 29 (Friday)
  • Issue closes – December 03 (Tuesday)
  • Issue size – Rs. 846.25 crores
  • Price band – Rs. 420 - 441 per equity share
  • Bid lot – 34 shares and in multiples thereof.

And here are some details of the company and further details on the IPO.

Company Details:

  • Suraksha Diagnostic Limited offer a one-stop integrated solution for pathology and radiology testing, and medical consultation services to their customers through their extensive operational network, consisting of their flagship central reference laboratory, 8 satellite laboratories (co-located with their diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya.
  • Their central reference laboratory has an accreditation from the College of American Pathologists, 3 of their laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and 3 of their advanced diagnostic centres hold National Accreditation Board for Hospitals & Healthcare Providers (“NABH”) accreditations. As of June 30, 2024, 44 of their diagnostic centres also housed 126 polyclinic chambers hosting 750+ specialized doctors for patient convenience.
  • Their radiology equipment consists of 24 CT and 13 MRI machines. As of June 30, 2024, their operational network comprises a diagnostic center network of (i) 13 hub centres, which are equipped to conduct all pathology sample collections, basic and advanced radiology tests; and (ii) their ‘spoke’ diagnostic centres which include their 11 medium centers, 23 small centres and 2 centres operated under public-private partnership (“PPP”) model, which are equipped to conduct all pathology sample collection and certain basic radiology tests, further supported by 166 sample collection centres (primarily franchised); and a laboratory network of (i) their flagship central reference laboratory; and (ii) 8 satellite laboratories which are co-located with certain hub centres.
  • Over the years, they have received several awards that recognize the strength of their brand and their focus on offering superior diagnostic services. For example, they were recognized for ‘excellence in exemplary trust & commitment towards diagnostic services’ and ‘excellence in quality diagnosis and convenient service in eastern India’ by Zee 24Ghanta in 2023 and 2022 respectively, as ‘business leader of the year’ in 2021 by the World Leadership Congress & Awards, and for ‘best customer service in healthcare’ and ‘best quality in service delivery’ by ABP News in 2019 and 2017 respectively.
Issue Size: Rs. 846.25 Cr.

Issue break-up:

QIB - 50 % of the offer - Rs. 423.12 Cr
NIB - 15 % of the offer - Rs. 126.94 Cr
RET - 35 % of the offer - Rs. 296.19 Cr

Listing: BSE & NSE

Registrar: KFin Technologies Limited

UPI : All Retail & NII Bidders (bids up to Rs. 5,00,000) Applications through brokers are compulsorily in UPI Mode

Note

Application made using third party UPI or ASBA Bank A/c are liable to be rejected.

The UPI Mandate acceptance time for Retail and NII Bidders (bids up to Rs. 5,00,000) shall expire at 5:00 PM on the closing day of the IPO i.e., Tuesday, December 03, 2024.

Not an Espresso customer, but still want to apply for the IPORs. Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.